CP 461

CAS No. 227619-96-7

CP 461( —— )

Catalog No. M34553 CAS No. 227619-96-7

CP 461 (UNII-68OJX9I7DT), a specific PDE2A inhibitor, is a novel pro-apoptotic compound that inhibits cyclic GMP phosphodiesterase but not cyclooxygenase-1 or -2.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 245 In Stock
10MG 363 In Stock
25MG 562 In Stock
50MG 759 In Stock
100MG 1014 In Stock
200MG 1376 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CP 461
  • Note
    Research use only, not for human use.
  • Brief Description
    CP 461 (UNII-68OJX9I7DT), a specific PDE2A inhibitor, is a novel pro-apoptotic compound that inhibits cyclic GMP phosphodiesterase but not cyclooxygenase-1 or -2.
  • Description
    CP 461 (UNII-68OJX9I7DT), a specific PDE2A inhibitor, is a novel pro-apoptotic compound that inhibits cyclic GMP phosphodiesterase but not cyclooxygenase-1 or -2. CP 461 inhibits the growth of a variety of human tumor cell lines in vitro and selectively induces apoptosis in cancer cell lines, but not in normal cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Apoptosis
  • Recptor
    Apoptosis | PDE
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    227619-96-7
  • Formula Weight
    420.91
  • Molecular Formula
    C25H22ClFN2O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    C(C(NCC1=CC=CC=C1)=O)C=2C=3C(/C(=C\C=4C=CN=CC4)/C2C)=CC=C(F)C3.Cl
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • 5-Methoxyuridine

    5-Methoxyuridine (Mo5U) is a purine nucleoside analog with a broad spectrum of antitumor activity, targeting malignant tumors of the inert lymphatic system and inducing apoptosis.

  • RAPTA-C

    RAPTA-C induces EAC cell cycle arrest and apoptosis via the mitochondrial and p53-JNK pathways, and can be used in the study of breast and ovarian cancer.

  • CSN5i-3 B

    CSN5i-3 is a potent, selective, and orally available inhibitor of the proteolytic subunit of the CSN complex, CSN5.